Background And Aims: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing interleukin (IL)-23p19 antagonists with ustekinumab, stratified by prior biologic exposure, in patients with moderate-to-severe Crohn's disease (CD).
Methods: Through a systematic review through August 17, 2024, we identified phase 2 and 3 RCTs comparing IL-23p19 antagonists vs. ustekinumab in adults with moderate-to-severe CD. Primary outcome was achieving clinical remission at ∼1y, and secondary outcomes were achieving endoscopic remission and serious adverse events. We performed subgroup analyses based on prior exposure to biologic therapy, primarily TNF antagonists. Certainty of evidence was appraised using the GRADE approach.
Results: We included five head-to-head RCTs with a treat-through design (n=2506), of which one was conducted exclusively in patients with prior TNF antagonist exposure. On meta-analysis, patients treated with IL-23p19 inhibitors may be more likely to achieve clinical remission (relative risk [RR], 1.18 [95% confidence interval [CI], 1.02-1.36]) [low certainty of evidence] and endoscopic remission (RR, 1.53 [1.07-2.20]) compared with ustekinumab. On subgroup analysis, IL-23p19 antagonists are probably more efficacious than ustekinumab in patients with prior biologic exposure (clinical remission: RR, 1.31 [1.16-1.48]; endoscopic remission: RR, 1.61 [1.27-2.05]) [moderate to high certainty], but not in biologic-naïve patients (clinical remission: RR, 0.99 [0.90-1.08]; endoscopic remission: RR, 1.16 [0.82-1.65]). IL-23p19 antagonists may be associated with a lower risk of serious adverse events as compared with ustekinumab (RR, 0.79 [0.61-1.02]).
Conclusions: IL-23p19 antagonists are probably more efficacious and safer than ustekinumab in patients with moderate-to-severe CD in patients with prior biologic exposure, but not in biologic-naïve patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14309/ajg.0000000000003406 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials.
Am J Gastroenterol
March 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Background And Aims: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing interleukin (IL)-23p19 antagonists with ustekinumab, stratified by prior biologic exposure, in patients with moderate-to-severe Crohn's disease (CD).
Methods: Through a systematic review through August 17, 2024, we identified phase 2 and 3 RCTs comparing IL-23p19 antagonists vs. ustekinumab in adults with moderate-to-severe CD.
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.
Adv Ther
February 2025
Salt Lake City Veterans Affairs Health, Salt Lake City, UT, USA.
Article Synopsis
- - Psoriatic arthritis (PsA) is a long-term inflammatory disease that requires ongoing treatment, with options like guselkumab and IL-17A inhibitors (ixekizumab, secukinumab) approved for use in adults by the FDA.
- - A retrospective analysis studied adults with PsA who started treatment with either guselkumab or IL-17A inhibitors, assessing how long they continued their therapy based on insurance claims data from July 2020 to June 2022.
- - Results showed that patients on guselkumab were significantly more likely to stick with their treatment for at least a year compared to those on IL-17A inhibitors, with longer median persistence and lower discontinuation rates for the gus
Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT).
Acta Derm Venereol
November 2024
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zürich, Zürich, Switzerland.
Article Synopsis
- * Results showed a significant reduction in the Psoriasis Area and Severity Index (PASI) after 3 and 18 months, with many patients achieving low PASI scores, indicating effective treatment.
- * Improvements in quality of life were noted, and no patients discontinued treatment due to adverse events, suggesting that tildrakizumab has a strong safety profile in a real-world setting.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Lancet
December 2024
Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease.
Methods: VIVID-1 was a global phase 3, randomised, double-blind, double-dummy, placebo-controlled and active-controlled, treat-through study.
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis.
Expert Opin Biol Ther
December 2024
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Introduction: Risankizumab (RZB) is a recombinant IgG humanized monoclonal antibody which selectively inhibits interleukin (IL)-23 though high-affinity binding of the p19 subunit. RZB was approved for use in Crohn's disease (CD) in 2022 and received regulatory approval for ulcerative colitis (UC) in the United States in June 2024.
Areas Covered: We will examine currently available therapies for UC, provide an overview of the IL-23 pathway, discuss available trial data for RZB in UC, and comment on how RZB may fit into the current UC treatment paradigm and future directions in the field.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!